Effective NAION neuroregenerative treatment using TXA127

Abstract

Current approaches to treatment of nonarteritic anterior ischemic optic neuropathy (NAION) rely on early retinal ganglion cell (RGC) neuroprotection. However, current neuroprotective approaches have been ineffective when administered late (>1d) after induction in rodent and primate NAION models. This is particularly problematic clinically, since nearly all patients are diagnosed at least a day post-symptom onset. We report on the success of a new neuroregenerative approach using TXA127, a pharmaceutical formulation of angiotensin (1-7) currently in Phase II for ischemic stroke.